Vaccine History

Edward Jenner's 1796 smallpox vaccination launched modern immunization. Pasteur's rabies vaccine (1885), Salk's polio vaccine (licensed 1955), Sabin's oral polio (1961), and dozens of others followed. mRNA technology (Karikó and Weissman, with 2023 Nobel) enabled COVID-19 vaccines developed in under a year. Vaccines have prevented an estimated 154 million deaths since 1974, about 146 million of them in children under 5.

1796
Jenner's first smallpox vaccination
154M
Deaths prevented by EPI vaccines since 1974
3.5-5M
Deaths prevented annually by vaccination (WHO)
11 mo
Time from COVID-19 sequence to first mRNA vaccine approval

Key insights

📜

From cowpox to mRNA in 225 years

1796: Edward Jenner uses cowpox material to immunize against smallpox. 1885: Louis Pasteur's rabies vaccine — first laboratory-developed vaccine. 1923: Diphtheria toxoid. 1955: Salk inactivated polio vaccine licensed. 1971: First MMR (measles-mumps-rubella) combination. 1980: WHO declares smallpox eradicated. 2006: Gardasil — first HPV vaccine, aimed at cervical cancer (hepatitis B vaccine had already been preventing liver cancer). 2020: COVID-19 mRNA vaccines authorised about 11 months after the sequence was published. The acceleration is real.

🌍

The Expanded Programme on Immunization saved 154M lives

WHO's EPI launched 1974 with six diseases (diphtheria, pertussis, tetanus, measles, polio, TB). Coverage grew from ~5% to ~84% globally. Lancet 2024 estimated 154M deaths prevented over 50 years, about 146M of them in children under 5 — equivalent to about 3 million a year. The intervention has been called the most cost-effective public health program in history.

🧬

mRNA technology has broader applications

mRNA vaccines for COVID-19 demonstrated speed (11 months from sequence to approval) and effectiveness (90%+ initial efficacy against severe disease). The technology is now being applied to: influenza (mRNA flu vaccines in Phase 3), RSV, cancer vaccines (personalized neoantigen vaccines for melanoma, pancreatic cancer), HIV, malaria. Whether the platform scales to all these applications is the major near-term question for vaccine development.

Major vaccine milestones since 1796

Year of first major use

Show data table
Major vaccine milestones since 1796
Year first major use
Smallpox 17961796
Rabies 18851885
Diphtheria 19231923
Yellow fever 19371937
Polio (Salk) 19551955
Polio (Sabin) 19611961
MMR 19711971
Hep B 19811981
HPV 20062006
Malaria (RTS,S) 20212021
COVID mRNA 20202020

Key Finding: Accelerating pace through the 20th century, with mRNA enabling faster development in the 2020s.

Global DTP3 vaccination coverage 1980–2024

% of one-year-olds receiving 3 doses

Show data table
Global DTP3 vaccination coverage 1980–2024
% DTP3
198022
199075
200072
201084
201986
202181
202485

Key Finding: From 22% (1980) to 85% (2024). COVID-era dip and partial recovery visible.

Methodology & caveats

How mRNA vaccines work

mRNA vaccines deliver instructions (in a lipid nanoparticle) for cells to make a specific viral protein. The immune system recognizes the protein and develops antibodies. Unlike traditional vaccines (which use weakened virus or inactivated virus or recombinant protein), mRNA vaccines don't require culturing the pathogen — speed is the major advantage. mRNA does not enter the cell nucleus or alter DNA.

Vaccine development timeline

Pre-COVID: typical vaccine development took 10-15 years. COVID-19 vaccines were developed in 11 months due to: (1) prior coronavirus research (SARS, MERS), (2) mRNA platform readiness, (3) global emergency funding, (4) parallel/accelerated Phase 1-3 trials, (5) regulatory cooperation (EUA pathways). Whether this speed can be replicated for other diseases depends on the prior research foundation.

Adjuvants and delivery

Most modern vaccines use adjuvants (substances that enhance immune response): aluminum salts, AS01 (Shingrix), MF59 (some flu vaccines), lipid nanoparticles for mRNA. Adjuvant development has been an underrated source of progress. Delivery mechanisms also matter — needle-free patches, micro-needle arrays, mucosal/oral vaccines are emerging for specific applications.

How lives saved are estimated

The 154 million is a modelled comparison with a world without EPI vaccines, built by the Vaccine Impact Modelling Consortium and WHO for 14 diseases, with measles accounting for about 60%. It relies on assumptions about how disease would have spread. A vaccine's year of "first major use" is also a judgement: smallpox inoculation predates Jenner, and licensed years differ by country, so the milestone chart is a guide to sequence, not exact dates.

What would change the picture

Malaria vaccines, RSV shots for infants and older adults, and a stronger TB vaccine, M72/AS01E, which is in Phase 3, would each add significantly to the toll prevented. On the other side, hesitancy and funding cuts threaten existing gains. US federal funding for mRNA research was cut back in 2025, which may slow the platform's spread beyond COVID.

Cite this page

GlobeChart. “Vaccine History.” Last updated 2026-10-31. https://globechart.com/health/vaccine-history/

Please also credit the original publisher named under each chart: WHO, CDC History of Vaccine Schedule; WHO/UNICEF WUENIC 2024. Spotted an error? Tell us.